SAGE's (SAGE) zuranalone Risk/Benefit Not Very Favorable, Opportunity is Niche - Analyst
- Wall Street gains evaporate, S&P 500 ends lower on Fed tightening timeline
- Tesla (TSLA) Reports Strong Q4 Beat, Achieves Record Vehicle Deliveries in 2021
- Intel (INTC) Reports Q4 Beat, Shares Down 2% on Guidance Miss
- Fed maintains federal funds rate at 0 to 1/4 percent, reduces assets purchases by another $30 billion/month and sees ending them in March
- Ackman Says Pershing Square Bought Over 3.1M Shares of Netflix (NFLX)
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Earlier today, Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months.
Of the 199 enrolled in the 50mg dose cohort, 149 (74.9%) responded (50% HAMD reduction from baseline), i.e. 50 (25%) did not respond. 3 withdrew from study.
Commenting on the announcement, Truist analyst Joon Lee, notes that the data came in “as largely expected.”
The analyst concludes: “Bottom line, 58% either did not respond or needing re-dosing, implying relapse. We don't think 50mg is a material improvement over 30mg and don't view risk/benefit is all that favorable. We think opportunity for zuranolone in MDD may be more niche.”
Truist maintains a "Hold" rating on the company's shares with $60 Price Target.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Mattel (MAT) Stock Price Is Up 10% Today
- UPDATE: Mizuho Securities Starts Oatly Group AB (OTLY) at Neutral
- Boeing (BA) PT Lowered to $234 at Vertical Research Partners
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!